Abstract
Introduction
The Invenia Automated Breast Ultrasound Screening (ABUS) is indicated as an adjunct
to mammography for breast cancer screening in asymptomatic women with high-density
breast tissue. ABUS provides time-efficient evaluation of the 3-dimensional recordings
within 3 to 6 minutes. The role and advantages of ABUS in everyday clinical practice,
especially in routine examination during neoadjuvant chemotherapy (NACT), is not clear.
The aim of this monocentric, noninterventional retrospective study is to evaluate
the use of ABUS in patients who are under NACT treatment for response control.
Methods
Regular sonographic response check with handheld ultrasound (HHUS) examination and
with ABUS were conducted in 83 women who underwent NACT. The response controls were
conducted every 3 to 6 weeks during NACT. The handheld sonography was performed with
GE Voluson S8. Handheld sonographic measurements and ABUS measurements were compared
with the final pathologic tumor size.
Results
There was no statistical difference between the measurements with HHUS examination
or ABUS compared with final pathologic tumor size (P = .47). The average difference from ABUS measured tumor size to final pathologic
tumor size was 9.8 mm. The average difference from handheld measured tumor size to
final pathologic tumor size was 9/3 mm. Both the specificity of ABUS and HHUS examination
in predicting pathologic complete remission was 100%.
Conclusion
ABUS seems to be a suitable method to conduct response control in neoadjuvant breast
cancer treatment. ABUS may facilitate preoperative planning and offers remarkable
time saving for physicians compared with HHUS examination and thus should be considered
for clinical practice
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Breast CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Neoadjuvant therapy in the treatment of breast cancer.Surg Oncol Clin N Am. 2014; 23: 505-523https://doi.org/10.1016/j.soc.2014.03.006
- Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation. Results from the National Cancer Database.J Am Coll Surg. 2015; 220: 1063-1069https://doi.org/10.1016/j.jamcollsurg.2015.02.011
- Neoadjuvant management of early breast Cancer. A clinical and investigational position statement.Oncologist. 2019; 24: 603-611https://doi.org/10.1634/theoncologist.2018-0228
- Neoadjuvant chemotherapy. Early response as a guide for further treatment: clinical, radiological, and biological.J Natl Cancer Inst Monographs. 2011; 2011: 138-141https://doi.org/10.1093/jncimonographs/lgr028
- Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy.Br J Radiol. 2011; 84: 612-620https://doi.org/10.1259/bjr/74430952
- Prädiktion der pathologischen Komplettremission nach neoadjuvanter Chemotherapie bei primärem Mammakarzinom mittels Interim Ultraschall, Shearwave-Elastografie und MRT.Ultraschall Med. 2018; 39: 422-431https://doi.org/10.1055/s-0043-111589
- Clinical imaging for the prediction of neoadjuvant chemotherapy response in breast cancer.Chin Clin Oncol. 2020; 9: 31https://doi.org/10.21037/cco-20-15
- Monitoring Early Breast Cancer Response to Neoadjuvant Therapy Using H-Scan Ultrasound Imaging. Preliminary Preclinical Results.J Ultrasound Med. 2019; 38: 1259-1268https://doi.org/10.1002/jum.14806
- Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.Ann Surg Oncol. 2011; 18: 3160-3163https://doi.org/10.1245/s10434-011-1919-5
- Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.Breast Cancer Res Treat. 2005; 92: 231-238https://doi.org/10.1007/s10549-005-2510-1
- Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.Ann Surg Oncol. 2006; 13: 1443-1449https://doi.org/10.1245/s10434-006-9086-9
- MRI staging after neoadjuvant chemotherapy for breast cancer. Does tumor biology affect accuracy?.Ann Surg Oncol. 2011; 18: 3149-3154https://doi.org/10.1245/s10434-011-1912-z
- Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer.Am J Surg. 2010; 199: 477-484https://doi.org/10.1016/j.amjsurg.2009.03.012
- Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.Ann Surg. 2006; 243: 257-264https://doi.org/10.1097/01.sla.0000197714.14318.6f
GE Healthcare Company. InveniaTM ABUS. Available at: https://www.ge-ultraschall.com/invenia-abus/
D'Orsi CJ, Sickles EA, Mendelson EB, Morris EA, , et al. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. Available at: https://www.acr.org/-/media/ACR/Files/RADS/BI-RADS/US-Reporting.pdf
- Should the hyperechogenic halo around malignant breast lesions be included in the measurement of tumor size?.Breast Cancer Res Treat. 2016; 156: 311-317https://doi.org/10.1007/s10549-016-3758-3
GE Healthcare Company. Invenia ABUS 2.0. Available at: https://www.gehealthcare.com/products/ultrasound/abus-breast-imaging/invenia-abus
- Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter.PLoS One. 2019; 14e0213749https://doi.org/10.1371/journal.pone.0213749
- Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer.AJR Am J Roentgenol. 2017; 208: 290-299https://doi.org/10.2214/AJR.16.17223
- Diagnostic performance and inter-observer concordance in lesion detection with the automated breast volume scanner (ABVS).BMC Med Imaging. 2013; 13: 36https://doi.org/10.1186/1471-2342-13-36
Article info
Publication history
Published online: May 25, 2021
Accepted:
May 17,
2021
Received in revised form:
May 16,
2021
Received:
March 4,
2021
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
